Genetic basis of cognitive disability by Flint, Jonathan
The importance of genetic influences on cognitive dis-
ability has been recognized for a long time, but molecular
analysis has only recently begun to yield insights into the
pathogenesis of this common and disabling condition.
The availability of genome sequences has enabled the
characterization of the chromosomal deletions and tri-
somies that result in cognitive disability, and mutations in
rare single-gene conditions are being discovered. The mol-
ecular pathology of cognitive disability is turning out to
be as heterogeneous as the condition itself, with unex-
pected complexities even in apparently simple gene-dele-
tion syndromes. One remarkable finding from studies on
X-linked mental retardation is that mutations in differ-
ent small guanosine triphosphate (GTP)–binding proteins
result in cognitive disability without other somatic fea-
tures. Advances are also being made in cognitive disabil-
ity with polygenic origins, such as dyslexia and autism.
However, the genetic basis of mild intellectual disability
has yet to be satisfactorily explained.
ognitive disability,or mental retardation (MR),
is a common condition, affecting about 3% of the pop-
ulation,
1,2 and is associated with a series of social and
medical handicaps. Yet we have almost no effective
treatment and little to offer beyond support to carers
and psychological or pharmacological intervention for
any comorbid behavioral disorder.The size of the prob-
lem is matched only by our ignorance as to its causes.
There can be little doubt that cognitive disability is
extremely heterogeneous,encompassing a gamut of both
social and biological conditions, yet, in an age when we
have the draft sequence of the human genome,it is dis-
appointing that we still know so little about the genetic
abnormalities that result in MR.Genetic abnormalities,
as we explain below,are without doubt a major contrib-
utor to moderate and severe cognitive disability, but
despite recent advances in uncovering the molecular
basis of some forms of MR, our understanding of the
pathogenesis of the condition is still limited. Conse-
quently,the chances of improving care are also limited;
inadequate understanding of the origins of cognitive dis-
ability remains a major challenge for medical practice.
The extent to which 
genes are involved
The causes of cognitive disability vary with the severity
of the condition: moderate-to-severe intellectual dis-
ability (defined as an intelligence quotient [IQ] score
less than 50) is much more likely to be due to a single
pathological cause (genetic or environmental) than mild
MR (defined as an IQ score between 50 and 70),which
is often thought to be multifactorial in origin. Chromo-
somal and genetic disorders account for 30% to 40% of
moderate-to-severe MR;environmental insults explain a
further 10% to 30%,and the cause is unknown in about
40% of cases.
3-7 Genetic and environmental causes
explain,in roughly equal proportions,about 30% of mild
intellectual disability; an etiological diagnosis is not
obtained in the remaining 70% of cases.
8-13
Table I summarizes data from epidemiological studies
of low IQ, following the convention of separating mild
disability from moderate to severe. Overall, the results
reveal a distinction between the two groups.While con-
troversy has long surrounded the extent to which genetic
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tion, there is now little doubt that moderate-to-severe
intellectual disability is due primarily to chromoso-
mal and genetic abnormalities. The largest individual
contributors are Down’s syndrome, chromosomal
rearrangements, and X-linked mental retardation
(XLMR) (Table I).Small chromosomal rearrangements,
affecting the ends (telomeres) of chromosomes have
emerged as a common cause in cases until recently
regarded as idiopathic,
14 and it is likely that a consider-
able proportion of cases of unknown etiology will also
be found to have a genetic origin.
The picture is less clear for IQ scores between 50 and 70.
The importance of polygenic influences is inferred from
the results of twin,family,and adoption studies for nor-
mal IQ measures,and rarely from direct investigation of
families with low IQ; studies evaluating biological and
environmental risk factors in this group are singularly
lacking, but there are indications that single-gene con-
ditions and chromosomal abnormalities may be more
frequent than previously assumed.
Table II presents data on the genetic basis of conditions
for which there is evidence that mutations give rise
directly to intellectual disability. The table lists condi-
tions where the genetic effects on intellectual function
are thought to be relatively immediate, that is to say
where no obvious developmental abnormality of the
brain or progressive destruction of neuronal tissue
results in cognitive impairment.The conditions are dis-
cussed in more detail in the following sections.
When we consider the pathogenesis of intellectual dis-
ability,it is important to bear in mind that the phenotype
involves multiple domains of intellectual functioning,
often broadly divided into verbal and performance skills,
but also encompassing capacities such as memory and
attention, where performance is not traditionally seen
as central to intellectual ability.Unfortunately,we do not
know whether the domains that psychologists recognize
correspond to the way genes operate, whether, for
instance,verbal and performance skills can be separated
at a genetic level.
Information is lacking about genetic influences on the
domains of both normal and abnormal intellectual func-
tioning.Studies of the heritability of intelligence,a mea-
sure of the extent to which genes contribute to the vari-
ation in intellectual functioning in the population,have
mostly been carried out on overall measures of cognitive
function, such as IQ, although more recent work on
speech and language development is beginning to indi-
cate that genetic effects that have more specific influ-
ences can be identified.
15,16 Similarly, there have been
few detailed psychometric investigations of people with
intellectual disability due to a specific genetic lesion,so
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Selected abbreviations and acronyms
AS Angelman syndrome
ATRX alpha-thalassemia X-linked mental retardation
syndrome 
CLS Coffin-Lowry syndrome 
CREB cyclic adenosine monophosphate response 
element–binding protein
CTAF conotruncal anomaly face syndrome
DGS DiGeorge syndrome
GAP GTPase-activating protein
GDI guanosine nucleotide dissociation inhibitor
GDP guanosine diphosphate
GTP guanosine triphosphate
GTPase guanosine triphosphatase
MAPK mitogen-activated protein kinase
MR mental retardation
NF1 neurofibromatosis type 1
PWS Prader-Willi syndrome
snoRNA small nucleolar RNA
VCFS velocardiofacial syndrome
XLMR X-linked mental retardation
Table I. The causes of intellectual disability. IQ, intelligence quotient.
Cause IQ less than 50 IQ between 50 and 70
Genetic 47 10
Down’s syndrome 33 5
Autosomal aneuploidy 2 1
Sex chromosome 
aneuploidy <1 1
Subtelomeric 
rearrangements 3 <1
Fragile X 2 <1
Single-gene disorder 6 2
Environmental 19 10
Prenatal 4 3
Perinatal 10 4
Postnatal 5 3
Unknown 34 80Genetic basis of cognitive disability - Flint Dialogues in Clinical Neuroscience - Vol 3 . No.1 . 2001
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we do not know whether cognitive functioning is abnor-
mal over all domains or whether there are discrete
abnormalities. In fact, as discussed later, there is some
evidence in favor of the latter hypothesis.
Genetic mapping techniques and molecular cloning have
made it possible to investigate disorders where the rela-
tionship between intellectual disability and genetic defect
might be immediate. These are conditions where there
are no noticeable alterations in brain structures and the
cause of cognitive impairment is difficult to find. In gen-
eral,this distinction is reflected in the division of MR into
syndromic and nonsyndromic conditions. In syndromic
MR, the phenotype includes additional physical abnor-
malities (such as facial dysmorphism or minor abnormal-
ities of the hands and feet), while in nonsyndromic MR
the only abnormality is cognitive impairment.
It might appear that genetic lesions are directly respon-
sible for intellectual disability more commonly in non-
syndromic than in syndromic conditions,but it should be
borne in mind that, without an understanding of the
pathogenesis, this is only an assumption. For example,
phenotypes vary considerably and mutations in the
same gene may give rise to both syndromic and non-
syndromic intellectual disability:mutations in RSK2 give
rise to Coffin-Lowry syndrome (CLS) and to nonspe-
cific intellectual disability,
17 and mutations in different
parts of the ATRX gene produce either syndromic or
nonsyndromic MR.
18 Nevertheless, some remarkable
advances in X-linked nonsyndromic intellectual dis-
ability are uncovering genes that act directly on cogni-
tion, probably through central nervous system (CNS)
development.
Syndromic intellectual disability
Mendelian disorders
Almost all recognized Mendelian intellectual disability
is X-linked.This is because X-linked recessive disease is
compatible with the occurrence of affected members in
multiple generations;it is therefore both recognizable as
an inherited condition and amenable to genetic mapping.
X-linked intellectual disability (ie, XLMR) is common:
the frequency is estimated to be 1.8 in 1000 males with a
carrier frequency of 2.4 in 1000 females.
19The number of
recognized conditions continues to increase: currently
210 have been described,126 mapped,and 32 cloned.
20
Fragile X syndrome is the commonest form of XLMR,
with a prevalence of approximately 1 in 5000 males and
causes intellectual disability in about 1 in 8000 females.
21
Affected individuals have a folate-sensitive fragile site in
the region Xq27.3, associated with an expansion of a
trinucleotide repeat (CGG) in the 5'-noncoding region
of a gene that encodes an RNA binding protein termed
FMR1.
Despite being one of the early triumphs of positional
cloning, the function of FMR1, and in particular how
its deficiency gives rise to intellectual disability, is still
not understood.In the normal brain,the FMR protein is
found in nearly all neurones.
22 It can bind RNA,includ-
ing its own transcript,and it has been postulated that the
FMR protein has a role in the machinery of translation
and,as it shuttles between nucleus and cytoplasm,that it
may be involved in mRNA export.
23 One explanation
for the effect of the gene on brain function is that it
plays a role in the maturation and pruning of dendritic
spines during brain development.
24
Mutations in factors that regulate gene expression are
emerging as an important genetic cause of intellectual
disability. Two syndromic conditions have been found
in which the gene acts as a transcriptional regulator
through its effect on chromatin. In Rett’s syndrome,
a progressive neurological disorder that affects females
almost exclusively, mutations have been found in 
methyl-CpG-binding protein 2 (MeCP2).
25 MeCP2
selectively binds CpG dinucleotides in the mammalian
genome and mediates transcriptional repression
through interaction with histone deacetylase and the
corepressor SIN3A. In the alpha-thalassemia X-linked
mental retardation syndrome (ATRX), mutations in
ATRX give rise to characteristic developmental abnor-
malities including severe MR,facial dysmorphism,uro-
genital abnormalities, and alpha-thalassemia.The gene
contains sequence motifs that indicate that it belongs
to a group of proteins that to bind to chromatin.
26 At a
molecular level,the mutation has effects on the pattern
of genomic methylation, consistent with the role of
ATRX in chromatin remodeling.
27The pleiotropic effects
of mutations in MECP2 and ATRX could result from
the regulated expression of a restricted class of genes.
Investigation of a syndromic MR condition, CLS, has
led to the discovery of the involvement of another sig-
naling pathway in cognitive impairment, namely the
MAPK-activated signaling pathway (MAPK for mito-
gen-activated protein kinase). CLS is characterized by
severe psychomotor retardation,facial and digital phys-Basic research
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Table II. The genetic basis of conditions for which there is evidence that mutations give rise directly to intellectual disability. ATRX, alpha-thal-
assemia X-linked mental retardation syndrome; XLMR, X-linked mental retardation; IL-1, interleukin-1; IQ, intelligence quotient; MAPK,
mitogen-activated protein kinase.
Disorder Genetic  Chromosomal Gene and/or product Function
abnormality region
  Nonspecific intellectual disability
XLMR Single gene mutation Xp IL1RACPL IL-1–signaling pathway
XLMR Single gene mutation Xp TM4SF2 Interaction with beta-1
integrins
XLMR Single gene mutation Xq Rho-GAP (OPHN1) Rho-GTPase cycle
XLMR Single gene mutation Xq PAK3 Rho-GTPase cycle
XLMR Single gene mutation Xq GDI1 Rab-GTPase cycle
XLMR Single gene mutation Xq ARHGEF6 Rho-GTPase cycle
XLMR Single gene mutation Xq FMR2 Unknown
  Syndromic intellectual disability (mutations in a single gene)
Fragile X (FRAXA) Single gene mutation Xq FMR1 Unknown
ATRX syndrome Single gene mutation Xq ATRX Abnormal methylation-
transcriptional regulator
Duchenne muscular dystrophy Single gene mutation Xp Dystrophin Cytoskeletal component
Rett’s syndome Single gene mutation Xq Methyl-CpG- Abnormal methylation-
binding protein 2 transcriptional regulator
Coffin-Lowry syndrome Single gene mutation Xp RSK2 Ras–MAPK-signaling
pathway
  Syndromic intellectual disability (segmental aneusomy)
Rubinstein-Taybi syndrome Single gene mutation 16p CBP Transcriptional
coactivator
Williams’ syndrome Segmental monosomy 7q LIM1 kinase Synapse formation
and maintenance?
Turner’s syndrome Segmental monsomy X Multiple genes? Unknown
Prader-Willi syndrome Segmental monosomy/ 15q Multiple genes? Unknown
parent-of-origin imprint
Angelman syndrome Single gene mutation/ 15q UBE3A Ubiquitin-mediated
parent-of-origin imprint protein degradation
DiGeorge, velocardiofacial, and Segmental monosomy 22q Multiple genes? Transcriptional
conotruncal anomaly face  regulators?
syndromes
Down’s syndrome Segmental trisomy 21q ?Minibrain
  Complex disorders
IQ Quantitative trait locus ?4p Unknown
Autism Quantitative trait locus ?1p, ?4p, ?6q, ?7q, Unknown
?13q, ?15q, /16p,ical anomalies, and progressive skeletal deformation.
The disorder was mapped by linkage to the region
Xp22.2 and mutations discovered in a positional candi-
date gene RSK2 (also known as RPS6KA3).
28 RSK2
mediates growth factor induction of cyclic adenosine
monophosphate response element–binding protein
(CREB) phosphorylation, as part of a signaling path-
way whereby Ras-MAPK and Ras signals are transmit-
ted to the nucleus to activate gene expression.Remark-
ably,mutations in RSK2 give rise to nonsyndromic MR:
patients in an XLMR family with neither facial, digital,
nor skeletal anomalies compatible with CLS, but with
mild MR, have been found to have a mutation in exon
14 of the gene, resulting in a conservative amino acid
change.
17The pathogenesis remains obscure.
Segmental aneusomy syndromes
A number of genetic conditions associated with intel-
lectual disability have been found to be due to small
chromosomal deletions or duplications (typically less
than 5 megabases) and are known as segmental aneu-
somy syndromes (see Table II).
29 The small size of some
of the regions has enabled a search for dosage-sensitive
genes.However,in order to prove that a deleted gene is
indeed dosage-sensitive, it has been necessary to find
families with point mutations in the gene that segregate
with intellectual disability.This has been achieved with
Rubinstein-Taybi syndrome (characterized by abnormal
craniofacial features,broad thumbs,and intellectual dis-
ability), which can arise from monosomy of a small
region in 16p13.3.
30 The responsible gene expresses the
CREB-binding protein (CBP).
31
Unfortunately,this approach has not been so successful
for other segmental aneusomies.Williams-Beuren syn-
drome is a neurodevelopmental disorder characterized
by congenital heart disease,infantile hypercalcemia,dys-
morphic facial features,and cognitive disability.It is due
to haploinsufficiency of genes in the region 7q11.
32 It is
known that mutations affecting the elastin gene give rise
to the supravalvular aortic stenosis,but there are still at
least 15 candidate genes that could be involved in the
unusual cognitive profile of the syndrome.These include
a number of transcriptional regulators,such as Williams’
syndrome transcription factor, which contains a plant
homeodomain (PHD), LIMK1, which contains one
PHD motif followed by a bromodomain, and the
WBSCR14/WS-bHLH gene, which encodes a basic-
helix–loop–helix leucine zipper, characteristic of a sub-
class of transcription factors.
33
Two clinically distinct disorders,Prader-Willi and Angel-
man syndromes (PWS and AS),arise from abnormalities
of a small region in 15q11-q13.
34 These syndromes have
characteristic and distinct neurobehavioral profiles: in
AS the retardation is severe (very few affected individ-
uals can talk) and there is ataxia, seizures, abnormal
EEG, microcephaly, facial dysmorphism, hyperactivity,
and paroxysmal laughter. By contrast, in PWS, the MR
may be only mild;there is a characteristic facial appear-
ance and a specific behavioral abnormality, ie, hyper-
phagia resulting in severe obesity.
Despite the phenotypic differences, the basic defect is
the same in the two disorders:a failure of parent-of-ori-
gin–specific gene expression. If both copies of chromo-
some 15 derive from the mother then the individual will
have PWS; if both are from the father then the pheno-
type is AS.The basic defect is not simply a dosage effect;
it turns out that about a quarter of cases of PWS are not
due to a deletion but to the inheritance of two maternal
copies of chromosome 15 (rather than the usual situation
of one maternal and one paternal). Conversely, two
paternal copies of chromosome 15 result in AS.The chro-
mosomal region is said to bear a parent-of-origin imprint,
of which the molecular signature is a difference in DNA
methylation.
35 Mutations in a ubiquitin protein ligase
gene (UBE3A) have been found in a few rare families
with AS.
36The gene product is part of a widely used ubiq-
uitin-mediated protein degradation pathway.
PWS is probably not the result of a defect in a single gene.
Seven genes (and candidate genes) have been identified in
the PWS region,all of which appear to be brain specific.
29
It is not known if the phenotype is due to an abnormality
in a single gene.However,there is now some evidence to
suggest that abnormal RNA editing,due to misregulation
of guide RNAs,mediates the defect in PWS.
The nucleolus contains a large number of small RNAs,
termed small nucleolar RNAs (snoRNAs); the major-
ity of these snoRNAs function in the posttranscriptional
modification of rRNA nucleotides. However, it is now
clear that the action of methylation guide snoRNAs goes
beyond the field of ribosome biogenesis.Recently,three
brain-specific snoRNAs, which are subject to genomic
imprinting in mice and humans, have been discovered
within the 15q11 critical region for PWS and AS.
37
Unusually, they do not have appropriate antisense ele-
ments, so their function is not clear, but one has a simi-
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41larity to the mRNA encoded by the gene for the sero-
tonin receptor–2C.The sequence matches a conserved
region subject to both alternative splicing and adeno-
sine-to-inosine editing.
38 Because of the known involve-
ment of serotonin in appetite control and cognition,this
finding raises the intriguing possibility that the defect in
PWS involves a defect in serotonin neurotransmission.
Similar problems beset attempts to understand how dele-
tions in the region 22q11 give rise to cognitive disabili-
ties.
39 DiGeorge (DGS), velocardiofacial (VCFS), and
conotruncal anomaly face (CTAF) syndromes are differ-
ent phenotypic manifestations of deletions within 22q11.
Both DGS and VCFS are associated with intellectual dis-
ability; additionally psychosis is found in some patients
with VCFS.The region most consistently contains at least
14 genes. Cloning and sequencing of the entire region
has not identified any obvious candidates for the cogni-
tive defect and it now seems likely that the syndromes
arise from combined monosomy of more than one gene.
Aneuploidy
Given the difficulties encountered in investigating the
segmental aneusomies, then trying to identify specific
genes responsible for the abnormalities found in aneu-
plodies, where there is an abnormality in the number
of a whole chromosome, might seem impossible. How-
ever comparison between individuals with partial ane-
uploidy of a chromosome has allowed the definition of
critical regions in both Down’s syndrome (trisomy 21)
40,41
and Turner syndrome (XO).
42
Candidate genes for some of the somatic features of
Turner syndrome have been proposed: SHOX/PHOG
encodes a homeodomain protein that may explain the
short stature,
43,44 while RPS4Y encodes an isoform of a
ribosomal small subunit protein.
45,46 Identification of
genes for features other than short stature has been
problematic. There are no candidates for the unusual
cognitive profile. However, there is one report that
Turner syndrome patients with a paternally derived X
chromosome have superior verbal abilities and skills
involved in social interactions.
47,48
In work on Down’s syndrome,attention has been focused
on the region 21q22.2 as a potential site for dosage-sen-
sitive genes that affect learning and behavior. On the
basis of transgenic mouse experiments, a homologue of
the Drosophila gene minibrain has been identified as a
candidate.
49,50 The gene encodes a tyrosine/serine kinase
expressed in developing neuroblasts and a human gene
lies in the Down’s syndrome–critical chromosomal region
21q22.However,as with the segmental aneusomies,there
is a proliferation of Down’s syndrome critical region
(DSCR) genes;as yet no definitive evidence of their role
in intellectual disability has been provided.
Nonsyndromic intellectual disability
Perhaps the most striking finding to emerge from the
study of nonsyndromic XLMR is the discovery of muta-
tions in genes affecting different components of the
Rho-signaling pathway (Table II).
51 Two genes,
oligophrenin-1 (OPHN1) and ARHGEF6,directly affect
the Rho-activation cycle.OPHN1 encodes a Rho-GAP
protein (GAP for GTPase [guanosine triphos-
phatase]–activating protein) that stimulates the intrinsic
GTPase activity of Rho, Rac, and Cdc42.
52 ARHGEF6
encodes a small cytoplasmic protein, homologous to
proteins that activate Rho-GTPases by exchanging
guanosine diphosphate (GDP) for guanosine triphos-
phate (GTP).
53 A third gene found to be mutated in
XLMR families is PAK3.
54 PAK3 may well be a down-
stream effector of the Rho-GTPases Rac and Cdc42
putting the message forward to the actin cytoskeleton
55
and to transcriptional activation.
A subfamily of Rab-GTPases is also implicated in MR.
56
Guanosine nucleotide dissociation inhibitor–1 (GDI1)
inhibits GDP dissociation from Rab3a by binding to
GDP-bound Rab proteins and appears to be crucial in
maintaining the balance between the GTP- and GDP-
bound forms of Rab3. Rab3a is a small GTP-binding
protein that functions in the recruitment of synaptic
vesicles for exocytosis
57,58 and is essential for long-term
potentiation (LTP) in hippocampal neurons.
59 All Rab
proteins are hydrophobic by nature and need GDI to
mediate membrane attachment and retrieval.
60,61 Rab
exists exclusively as a soluble complex with GDI in the
cytoplasm, where it forms a reservoir to deliver Rab to
the membrane during assembly of a transport vesicle.
How might the biology of the small GTP-binding pro-
teins explain human cognitive function? One possibility is
that mutations disrupt the normal development of axonal
connections.
62-64This would fit with the known cell biology
of the Rho-GTPases.
65 Growth cones of developing axons
find their way through the brain by sampling molecular
signals, helped by GTPases.
66 Whereas Cdc42 and Rac1
are involved in the formation of lamellipodia and filopo-
Basic research
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67 inhibition of Rho,Rac,and Cdc42 also reduces den-
drite formation.
68 Cognitive dysfunction could therefore
be due to a failure to establish correct neuronal connec-
tions during CNS development.
A second possibility is that synaptic function is compro-
mised. This view is supported by what is known about
the function of Rab3a in exocytosis.
69 Synaptic vesicles
contain Rab3a, the most abundant Rab protein in the
brain and,in one model,exocytosis leads to the dissoci-
ation of Rab3a from the vesicle.
58 Since Rab3a-deficient
mice have no fundamental deficits in synaptic vesicle
exocytosis,
57 the protein is not essential to the process,
but is required to maintain a normal reserve of synaptic
vesicles.The GDI1 mutation,by disrupting Rab3a traffic,
is expected to alter neurotransmitter release, which
might,in turn,account for the intellectual impairment.
Why is the effect of the mutation specific? Both the
developmental and synaptic transmission account of
Rho-GTPase involvement must explain why only neu-
rones involved in cognitive systems are disrupted. One
likely explanation is that the mutations only partly dis-
rupt the brain system on which they operate,but it could
also be that compensatory mechanisms, effective in
other cell types,fail when it comes to neuronal processes
involved in cognitive processing.
Interestingly, there is also evidence that the cognitive
defects associated with neurofibromatosis type 1 (NF1)
derive from an effect on the Ras pathway.NF1 is a com-
mon familial tumor syndrome with an incidence of 1 in
3500. It is a Mendelian autosomal dominant trait pri-
marily affecting brain and skin. Some 30% to 65% of
the affected children have learning difficulties,but only
4% to 8% have MR.
70,71 The NF1 gene, neurofibromin,
has a GAP-related domain linking it to signal transduc-
tion pathways.
72 Molecular investigation of a family with
NF1 identified a mutation that disabled the Ras-
GTPase–activating function.
73Affected children had an
IQ range of 80 to 89 and impairment in both language
and motor development, indicating that the GAP of
neurofibromin is critical to the development of these
functions.
The function of other nonsyndromic XLMR genes is
less clear (Table II). TM4SF2 encodes a member of a
group of proteins that complex with integrins, proteins
that function as αβ -heterodimers mediating adhesive
interactions with the extracellular matrix and also acting
to transduce signaling.Evidence for the role of integrins
in human cognition came from the isolation of a muta-
tion in TM4SF2 in a patient with nonsyndromic
XLMR.
74Analysis of the expression pattern of TM4SF2
using mRNA in situ hybridization on mouse brain sec-
tions revealed that it is ubiquitously expressed early in
brain development.
IL1RAPL (interleukin-1 [IL-1] receptor accessory pro-
tein–like) has, as its name suggests, homology to IL-1
receptor accessory protein. The function of the FMR2
gene,associated with mild intellectual disability gene,is
also unknown: it encodes a nuclear protein that may
regulate transcription and available data indicate that
it functions at the cell surface.The IL1RAPL gene was
identified by analyzing overlapping microdeletions in
Xp22.1-21.3 associated with nonspecific MR. Using
DNA sequence from this region,a gene was found with
a weak homology to interleukin-1 receptor accessory
protein. Nonoverlapping deletions encompassing the
IL1RAPL gene were found
75 and a point mutation in
this gene was discovered segregating with MR in an
unrelated family. The nonsense mutation introduces a
premature stop codon that leads to a barely detectable
level of IL1RAPL transcript.The expression pattern of
IL1RAPL mRNA on mouse brains is also consistent
with a role in learning in memory, as it is present in the
granular layer of the dentate gyrus and the pyramidal
layer of the hippocampus.
Examples of autosomal single-gene defects resulting in
intellectual disability are very rare.However,there is one
good example of a four-generation family with a speech
and language disorder that,remarkably,segregates as an
autosomal dominant condition.
76 The speech and lan-
guage difficulties are part of a broader syndrome that
includes a lower than average IQ;affected members also
have a pronounced impairment in articulation.
77The gene
has been mapped to the chromosomal region 7q,
78 a
region also implicated in studies of autism, a polygenic
condition,one characteristic of which is abnormal speech
development.
79 Molecular characterization of this
unusual Mendelian disorder could well provide new
insights into the biology of language development.
Polygenic effects 
on intellectual disability
There are a small number of rare developmental disor-
ders that result in intellectual disability and are thought
to have a polygenic basis.Among these, autism (a con-
dition marked by abnormal language and social devel-
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opment, together with obessional behavior) is known
to have an extremely high heritability (over 90%).
80The
difficulties besetting attempts to identify the predispos-
ing loci are common to all attempts to dissect the
genetic basis of complex, polygenic phenotypes, with
different studies reporting different findings (Table
II).
79,81 At present, there is some replicated evidence
pointing to a locus on chromosomal region 7q.
82 Map-
ping the loci determining quantitative variation in IQ
has yet to yield convincing results.There has been more
success mapping the genes that influence a specific intel-
lectual function, namely reading. A locus at 6p21.3 is
one of the few replicated findings in behavioral genetics,
with a number of studies reporting that the locus is rel-
atively specific for reading disability.
83-87
Assuming that the approach does work and that local-
izations for polygenic variation in intellectual disability
are found, we are faced with the question of whether
genes that determine variation overlap with the muta-
tions described above.Conceivably,the same pathways
are involved,in which case the combination of mapping
and molecular pathology screening would be ideally
placed to identify the many genes that are responsible
for intellectual disability.❏
This work was supported by the Wellcome Trust.
Bases genéticas de la incapacidad cognitiva
Desde hace bastante tiempo se ha reconocido la
influencia genética en la incapacidad cognitiva,
pero sólo recientemente el análisis molecular ha
comenzado a producir conocimientos acerca de
la patogénesis de esta común e incapacitante
enfermedad. La disponibilidad de las secuencias
del genoma ha permitido la caracterización de
las supresiones y trisomías cromosómicas que lle-
van a una incapacidad cognitiva y se han descu-
bierto mutaciones en las raras condiciones de
gen único. La patología molecular de la incapa-
cidad cognitiva está resultando ser tan hetero-
génea como la condición misma de la incapaci-
dad, con complejidades insospechadas en
síndromes aparentemente simples de supresión
de genes. Un hallazgo notable de los estudios de
retardo mental relacionado con el cromosoma X
es que las mutaciones en diferentes proteínas
pequeñas unidas a guanosina - trifosfato (GTP)
se traducen en incapacidad cognitiva sin otras
características somáticas. También se están reali-
zando avances en la incapacidad cognitiva con
orígenes poligénicos como la dislexia y el autis-
mo. Sin embargo, las bases genéticas de la inca-
pacidad intelectual leve aún deben ser explica-
das satisfactoriamente.
Bases génétiques du déficit cognitif
Si l'importance de la génétique dans les déficits
cognitifs est connue depuis longtemps, ce n'est
que depuis peu que l’analyse moléculaire est en
mesure de fournir un nouvel éclairage sur la
pathogenèse de ces états tant courants qu'inva-
lidants. Grâce aux séquences génomiques dispo-
nibles dans les bases de données on a pu carac-
tériser des délétions chromosomiques et des
trisomies à l’origine de déficits cognitifs, tandis
que des mutations monogéniques dans certaines
formes rares sont en cours de découverte. De
fait, la pathologie moléculaire du déficit cognitif
s’avère aussi hétérogène que le déficit lui-même,
présentant des complexités inattendues, même
dans certains syndromes de délétion génique
apparemment simples. Des études portant sur le
retard mental lié au chromosome X ont permis la
découverte remarquable de mutations sur diffé-
rentes petites protéines liantes de la guanosine
triphosphate (GTP) qui entraînent un déficit
cognitif en l'absence de tout autre expression
somatique. Des progrès sont également en cours
dans l’exploration des déficits cognitifs d'origine
polygénique comme la dyslexie et l’autisme. Il
n'en reste pas moins qu'en dépit de ces acquisi-
tions récentes, les bases génétiques du déficit
cognitif léger attendent toujours une explication
satisfaisante.Genetic basis of cognitive disability - Flint Dialogues in Clinical Neuroscience - Vol 3 . No.1 . 2001
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